Literature DB >> 19885979

Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment?

Bob Roozenbeek1, Andrew I R Maas, Hester F Lingsma, Isabella Butcher, Juan Lu, Anthony Marmarou, Gillian S McHugh, James Weir, Gordon D Murray, Ewout W Steyerberg.   

Abstract

OBJECTIVE: Heterogeneity of patients is a common problem in randomized controlled trials (RCTs) in various fields of clinical research. We aimed to investigate the potential benefits of different approaches for dealing with heterogeneity in a case study on traumatic brain injury (TBI). DESIGN AND
SETTING: Statistical modeling studies in three surveys and six randomized controlled trials. PATIENTS: Individual patient data (n = 8033) from the IMPACT database.
INTERVENTIONS: We investigated the statistical power and efficiency of randomized controlled trials (RCTs) in relation to (1) selection according to baseline characteristics, (2) prognostic targeting (i.e., excluding those with a relatively extreme prognosis), and (3) covariate-adjusted analysis. Statistical power was expressed as the required sample size for obtaining 80% power and efficiency as the relative change in study duration, reflecting both gains in power and adverse effects on recruitment. Uniform and targeted treatment effects were simulated for 6 month unfavorable outcome.
RESULTS: For a uniform treatment effect, selection resulted ina sample size reduction of 33% in the surveys and 5% in the RCTs, but decreased recruitment by 65% and 41%, respectively. Hence, the relative study duration was prolonged (surveys: 95%; RCTs: 60%). Prognostic targeting resulted in sample size reductions of 28% and 17%, and increased relative study duration by 5% in surveys and 11% in the RCTs. Covariate adjustment reduced sample sizes by 30% and 16%, respectively, and did not affect recruitment. For a targeted treatment effect, the sample size reductions by selection (surveys: 47%; RCTs: 20%) and prognostic targeting (surveys: 49%; RCTs: 41%) were larger and adverse effects on recruitment smaller.
CONCLUSIONS: The benefits of selection and prognostic targeting in terms of statistical power are reversed by adverse effects on recruitment. Covariate adjusted analysis in a broadly selected group of patients is advisable if a uniform treatment effect is assumed, since there is no decrease in recruitment.

Entities:  

Mesh:

Year:  2009        PMID: 19885979     DOI: 10.1097/ccm.0b013e3181ab85ec

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  25 in total

1.  Covariate adjustment increased power in randomized controlled trials: an example in traumatic brain injury.

Authors:  Elizabeth L Turner; Pablo Perel; Tim Clayton; Phil Edwards; Adrian V Hernández; Ian Roberts; Haleema Shakur; Ewout W Steyerberg
Journal:  J Clin Epidemiol       Date:  2011-12-09       Impact factor: 6.437

Review 2.  Multi-modality neuro-monitoring: conventional clinical trial design.

Authors:  Alexandros L Georgiadis; Yuko Y Palesch; David Zygun; J Claude Hemphill; Claudia S Robertson; Peter D Leroux; Jose I Suarez
Journal:  Neurocrit Care       Date:  2015-06       Impact factor: 3.210

3.  Sample size estimation for stratified individual and cluster randomized trials with binary outcomes.

Authors:  Lee Kennedy-Shaffer; Michael D Hughes
Journal:  Stat Med       Date:  2020-01-31       Impact factor: 2.373

4.  Outcomes and statistical power in adult critical care randomized trials.

Authors:  Michael O Harhay; Jason Wagner; Sarah J Ratcliffe; Rachel S Bronheim; Anand Gopal; Sydney Green; Elizabeth Cooney; Mark E Mikkelsen; Meeta Prasad Kerlin; Dylan S Small; Scott D Halpern
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

5.  Early recognition of poor prognosis in Guillain-Barre syndrome.

Authors:  C Walgaard; H F Lingsma; L Ruts; P A van Doorn; E W Steyerberg; B C Jacobs
Journal:  Neurology       Date:  2011-03-15       Impact factor: 9.910

Review 6.  A systematic review of early prognostic factors for persisting pain following acute orthopedic trauma.

Authors:  Fiona J Clay; Wendy L Watson; Stuart V Newstead; Roderick J McClure
Journal:  Pain Res Manag       Date:  2012 Jan-Feb       Impact factor: 3.037

7.  New considerations in the design of clinical trials for traumatic brain injury.

Authors:  Bob Roozenbeek; Hester F Lingsma; Andrew Ir Maas
Journal:  Clin Investig (Lond)       Date:  2012-02

Review 8.  IMPACT recommendations for improving the design and analysis of clinical trials in moderate to severe traumatic brain injury.

Authors:  Andrew I R Maas; Ewout W Steyerberg; Anthony Marmarou; Gillian S McHugh; Hester F Lingsma; Isabella Butcher; Juan Lu; James Weir; Bob Roozenbeek; Gordon D Murray
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

9.  Inability to obtain deferred consent due to early death in emergency research: effect on validity of clinical trial results.

Authors:  Tim C Jansen; Jan Bakker; Erwin J O Kompanje
Journal:  Intensive Care Med       Date:  2010-08-06       Impact factor: 17.440

10.  Prediction of two month modified Rankin Scale with an ordinal prediction model in patients with aneurysmal subarachnoid haemorrhage.

Authors:  Roelof Risselada; Hester F Lingsma; Andrew J Molyneux; Richard S C Kerr; Julia Yarnold; Mary Sneade; Ewout W Steyerberg; Miriam C J M Sturkenboom
Journal:  BMC Med Res Methodol       Date:  2010-09-29       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.